Lifestyle Medicine

The term and early research

James Rippe, writing in 2018 as editor-in-chief of the American Journal of Lifestyle Medicine, states that a multi-author textbook he edited in 1999 coined the term lifestyle medicine and defined it as the discipline of studying how daily habits and practices affect prevention and treatment of disease, often alongside drug or surgical therapy. This is the author's own account, and he declares an editorial role and a research institute that studies activity, nutrition and weight management.

Trials of lifestyle change in defined patient groups predate the term in some cases. The Lifestyle Heart Trial, published in The Lancet in 1990, randomised 48 people with coronary artery disease to a multicomponent programme or usual care for one year, and the Diabetes Prevention Program reported its main results in 2002. The sources reviewed do not say whether these investigators saw themselves as part of one field.

Professional bodies and certification

A 2022 commentary by two authors affiliated with the American College of Lifestyle Medicine (ACLM) and the American Board of Lifestyle Medicine (ABLM) says that ACLM was founded in 2004 and that the ABLM launched its first certification examinations in 2017. It reports that by January 2022 about 1,850 United States physicians had been certified, plus 1,375 physicians in 72 countries certified in partnership with the International Board of Lifestyle Medicine. One passage of the same text gives a different figure for United States diplomates, so the numbers need checking.

In the United Kingdom, the British Society of Lifestyle Medicine (BSLM) states on its website that it was founded in 2016 by two general practitioners and a surgeon. The site lists a core accreditation course and a maintenance of certification programme for clinicians.

Status as a specialty and the age of the idea

Sources describe the field's specialty status differently. In October 2025 the American Board of Preventive Medicine announced that it had asked the American Board of Medical Specialties (ABMS) to approve a Focused Practice designation in lifestyle medicine, with review stages scheduled for March and June 2026. The page reviewed does not report the outcome, and this record did not confirm it. The BSLM said in 2021 that lifestyle medicine was not a regulated medical speciality.

The 2022 certification commentary describes the field as recalling the healing power of diet and physical activity dating back 2,500 years to Hippocrates. That is the authors' framing. It does not show a continuous tradition linking ancient advice to the structured, trial-tested programmes discussed below, the earliest of which in this record dates from 1990.

Definitions in use

ACLM, as quoted in the 2022 commentary, defines the field as the use of evidence-based lifestyle therapeutic intervention as a primary modality, naming a whole-food, plant-predominant eating pattern alongside physical activity, sleep, stress management, avoiding risky substances and social connection, delivered by trained and certified clinicians. Rippe's 1999 definition was wider and described a discipline that often sits alongside drug or surgical therapy.

The BSLM defines it as evidence-based clinical care that supports behaviour change through person-centred techniques, and says it acknowledges the need for action on socio-economic determinants of health. Its website also says it does not adhere to any single approach to nutrition, which differs from the plant-predominant emphasis in the ACLM wording.

The pillars are not fixed

Lists of domains vary by source and date. Rippe's 2018 review focused on five aspects: physical activity, nutrition, weight management, avoiding tobacco and stress reduction or mental health. The BSLM in 2021 named sleep, social connection, connection with nature and relaxation as less well studied contributors. A 2026 article by authors including ACLM staff says the six-pillar framework had not included spirituality but that recent revisions allow initial integration of meaning, purpose and spirituality.

Related and overlapping terms

The 2022 commentary distinguishes lifestyle medicine from preventive medicine, saying the pillars can prevent disease but are also used to treat existing chronic disease with the aim of remission. A 2021 analysis in the British Journal of General Practice notes that the term is applied broadly and that, in the United States, board certification involves a definition centred on assisting individuals and families to adopt and sustain health-improving behaviours.

The same analysis argues that the term is sometimes used alongside integrative or functional medicine. The BSLM replied in 2021 that it is not affiliated with functional or integrated medicine, does not teach reflexology, homeopathy, herbalism or naturopathy in its diploma, and does not endorse any alternative medical practice.

Clinicians and training routes

In the ABLM route described in 2022, physicians must hold ABMS board certification in a primary discipline, complete a case study, meet continuing medical education requirements and pass an examination. The commentary says a lifestyle medicine residency curriculum has been integrated into 200 residency programmes. The BSLM describes members from primary and secondary care, allied and public health professions, science, education and research, and says it trains clinicians in group consultations, health coaching, motivational interviewing, social prescribing and shared decision making.

What programmes in trials involved

The sources reviewed do not give a standard consultation sequence, so the clearest descriptions come from trials. The Diabetes Prevention Program lifestyle arm aimed for at least 7 percent weight loss and at least 150 minutes of physical activity a week. Look AHEAD used decreased calorie intake and increased activity for weight loss, and the Lifestyle Heart Trial combined a low-fat vegetarian diet, stopping smoking, stress management training and moderate exercise.

The DiRECT trial in Scottish and English primary care used a formula diet of 825 to 853 kilocalories a day for three to five months, stepped food reintroduction and structured support, and withdrew antidiabetic and blood pressure drugs at the start. These are trial protocols for specific groups and are not a template for individual care.

Claims made by professional bodies

The ACLM definition quoted in 2022 says the approach aims to prevent, treat and often reverse chronic disease, and the BSLM says it supports clinicians to help patients prevent, manage and even reverse many chronic conditions. The 2022 commentary says the approach goes beyond prevention by treating existing chronic disease with the aim of remission. Here, reverse and remission are claims by the bodies themselves, and their meaning depends on the condition and the outcome measured.

Conditions covered in the sources reviewed

Rippe's 2018 review applies the approach to coronary heart disease, diabetes, obesity and cancer, and notes that lifestyle recommendations appear in many guidelines for chronic metabolic disease. The trials reviewed for this record address type 2 diabetes prevention, type 2 diabetes remission, coronary atherosclerosis and cardiovascular events in people with diabetes. Uses in mental health, sleep disorders or neurological disease were not reviewed here.

Preventing type 2 diabetes

The Diabetes Prevention Program randomised 3,234 non-diabetic adults with raised glucose to placebo, metformin or an intensive lifestyle programme. Over an average 2.8 years, diabetes incidence per 100 person-years was 11.0 with placebo, 7.8 with metformin and 4.8 with lifestyle, a 58 percent reduction (95% confidence interval 48 to 66) against placebo. At 15 years the reduction was 27 percent (hazard ratio 0.73), with cumulative incidence of 55 percent in the lifestyle group and 62 percent with placebo, and the between-group difference declined over time.

Type 2 diabetes remission

DiRECT, an open-label cluster-randomised trial in 49 primary care practices, enrolled 306 adults aged 20 to 65 with type 2 diabetes diagnosed within six years. At 12 months, 46 percent of the intervention group and 4 percent of controls were in remission, defined as HbA1c below 6.5 percent after at least two months off antidiabetic drugs. A 2026 systematic review of six studies, two of them randomised, reported moderate-certainty pooled remission risk ratios of 7.42, with remission in single-arm studies of very low certainty.

Coronary disease and long-term outcomes

The Lifestyle Heart Trial randomised 28 people to a multicomponent programme and 20 to usual care, and after one year average diameter stenosis regressed in the programme group and progressed in controls. This is a small trial of 195 lesions. Observational studies relate lifestyle factors to outcomes: INTERHEART, a case-control study in 52 countries, found nine factors accounted for 90 percent of population attributable risk of myocardial infarction in men and 94 percent in women, and a cohort analysis projected longer life expectancy with five low-risk factors. These are associations, not trial effects.

Null and partial findings

Look AHEAD randomised 5,145 overweight or obese adults with type 2 diabetes to intensive lifestyle intervention or diabetes support and education. Weight loss was greater with the intervention, but the trial stopped early for futility at a median 9.6 years, and cardiovascular events did not differ (hazard ratio 0.95, 95% confidence interval 0.83 to 1.09). In the 15-year Diabetes Prevention Program follow-up, the combined microvascular outcome did not differ overall between groups, though it was lower in women with lifestyle intervention.

Programmes versus individual pillars

Most of the trials above test a bundled programme in a particular group, such as people with raised glucose or recent type 2 diabetes. Results cannot be assigned to one pillar or transferred to another condition. None of the sources reviewed for this record tested sleep or social connection as a stand-alone intervention, so the evidence for the pillar framework as a whole is uneven.

Published criticism and reply

A 2021 analysis in the British Journal of General Practice raised three concerns: a risk that pseudoscience may enter under an evidence-based label, commercial conflicts of interest, and a risk of widening health inequalities through a focus on individual behaviour. It also argued that trial results may not carry over to real-world practice, citing weight loss programmes taken up by fewer than a third of at-risk patients. The BSLM replied that it shares concerns about evidence and regulation and aims to set standards and accredit practice.

Several sources are produced by bodies that promote the field. The 2022 commentary authors are affiliated with ACLM and ABLM, Rippe edits the American Journal of Lifestyle Medicine, and the 2026 article includes ACLM staff among its authors. This does not show bias but means the sources are not independent of the field.

Adverse events in trials

In the Diabetes Prevention Program, gastrointestinal symptoms occurred at 12.9 events per 100 person-years with lifestyle intervention, 30.7 with placebo and 77.8 with metformin, while musculoskeletal symptoms were 24.1, 21.1 and 20.0 respectively. No deaths were attributed to the study interventions. In DiRECT, nine serious adverse events occurred in seven of 157 intervention participants and two in two control participants, and two events in one participant were judged possibly related.

Medicines and exercise

In DiRECT, antidiabetic and antihypertensive drugs were withdrawn as part of a supervised programme. The 2026 systematic review states that implementation requires structured medication withdrawal protocols and long-term primary care follow-up. An American Diabetes Association position statement notes that insulin and insulin secretagogues can cause hypoglycaemia during and after exercise and that doses may need adjusting. Changes to prescribed medicines belong with the prescribing clinician, and lifestyle programmes should not delay or replace necessary care.

Training, titles and regulation

ABLM certification is described as additional to a primary ABMS board certification, and the BSLM said in 2021 that the term lifestyle medicine can be used by non-regulated professionals. The 2021 analysis stated that BSLM associate membership was then open to non-clinical therapists, which describes that year and was not rechecked. Voluntary certification and accreditation by professional bodies are described; no statutory regulation specific to the term was reported in the sources reviewed.